Meet the team behind c4c! We are a diverse group of people from many different backgrounds, but all of us are working towards a common goal: better medicines for children through European clinical trials. Today’s spotlight is on Sofia Jacob, who oversees multiple activities within c4c to ensure they are completed in time. Sofia…
DetailsCall for Experts 2022 In order to expand our database we are now seeking experts interested to be part of Clinical or Methodology Expert Groups and who want to contribute at providing advice. One task of the c4c consortium is to deliver the scientific feasibility advice needed to improve child health and paediatric…
DetailsHow paediatric drug development and use could benefit from OMICs: A c4c expert group white paper – Neumann – – British Journal of Clinical Pharmacology – Wiley Online Library The safety and efficacy of pharmacotherapy in children, particularly preterms, neonates and infants, is limited by a paucity of good-quality data from prospective clinical drug trials.…
Detailsc4c: Paediatric pharmacovigilance: Methodological considerations in research and development of medicines for children – A c4c expert group white paper by Aurich et al British Journal of Clinical Pharmacology – Wiley Online Library Children frequently respond differently to therapies compared to adults. Differences also exist between Paediatric age groups for pharmacokinetics and pharmacodynamics in both…
DetailsMeet the team behind c4c! We are a diverse group of people from many different backgrounds, but all of us are working towards a common goal: better medicines for children through European clinical trials. Today’s spotlight is on Lionel Tan, one of the industry representatives helping to steer the direction of c4c. Lionel Tan…
Details
